These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29359848)

  • 1. Optimizing the management of hypoglycaemia in individuals with type 2 diabetes: A randomized crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens.
    Krebs JD; Weatherall M; Corley B; Wiltshire E; McTavish L
    Diabetes Obes Metab; 2018 May; 20(5):1256-1261. PubMed ID: 29359848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial.
    McTavish L; Corley B; Weatherall M; Wiltshire E; Krebs JD
    Diabet Med; 2018 Mar; 35(3):339-346. PubMed ID: 29285796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight-based hypoglycaemia treatment protocol for adults with Type 1 diabetes: a randomized crossover clinical trial.
    McTavish L; Krebs JD; Weatherall M; Wiltshire E
    Diabet Med; 2015 Sep; 32(9):1143-8. PubMed ID: 25683747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of an education programme (MEDIAS 2 BSC) of non-intensive insulin treatment regimens for people with Type 2 diabetes: a randomized, multi-centre trial.
    Hermanns N; Ehrmann D; Schall S; Maier B; Haak T; Kulzer B
    Diabet Med; 2017 Aug; 34(8):1084-1091. PubMed ID: 28257159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact?
    Choudhary P; Davies C; Emery CJ; Heller SR
    Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA.
    Mauricio D; Meneghini L; Seufert J; Liao L; Wang H; Tong L; Cali A; Stella P; Carita P; Khunti K
    Diabetes Obes Metab; 2017 Aug; 19(8):1155-1164. PubMed ID: 28251792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
    Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
    Farngren J; Persson M; Ahrén B
    Diabetes Obes Metab; 2018 Aug; 20(8):1911-1920. PubMed ID: 29645341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetologia; 2023 Jul; 66(7):1208-1217. PubMed ID: 37037948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.